Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Model scores of the 29,894 trials active now.

Model score 39% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-10-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: breast cancerher2longpaclitaxelcell
  Phrases that lowered it: participantsindividualschildrencombinationknown
• Sponsor's past termination rate: 17.5% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 88 (lowers risk) · Sponsor's track record
• Disease area, dermatology: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 275 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Drug's FAERS reports before start: 165922 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 30676 (lowers risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports with a death: 23.0% (raises risk) · Drug's FDA history
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca NCT02041429 · started 2014 · scored riskier than 99% of active trials completed
• Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer NCT02066532 · started 2014 · scored riskier than 99% of active trials completed
• Ruxolitinib for Premalignant Breast Disease NCT02928978 · started 2018 · scored riskier than 99% of active trials completed
• Ruxolitinib in Estrogen Receptor Positive Breast Cancer NCT01594216 · started 2012 · scored riskier than 97% of active trials completed
• Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT02713386 · started 2016 · scored riskier than 28% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.